【摘要】 为对游离前列腺特异性抗原 (fPSA) /总前列腺特异性抗原 (tPSA)比值在临床应用中的价值进行评估 ,本文应用电化学发光免疫测定法 ,检测了 3 8例Pca、68例BPH患者以及 43名无前列腺疾病的正常男子血清tPSA和fPSA含量 ,并计算fPSA/tPA的比值。结果表明单独以血清tPSA大于 4.0 μg/L作为诊断Pca的标准 ,其灵敏度和特异性分别为 84.2 %、75 .0 %。若以血清fPSA/tPSA小于 0 .13作为诊断Pca的限定值 ,当血清tPSA小于 2 .0 μg/L时 ,fPSA/tPSA比值的灵敏度和特异性分别为 10 0 .0 %、5 7.0 % ;当血清tPSA大于 2 0 .0 μg/L时 ,fP SA/tPSA比值的灵敏度和特异性分别为 62 .1%、66.7% ,而当血清tPSA水平在 2 -2 0 μg/L时 ,fPSA/tPSA比值的灵敏度和特异性分别为 93 .6%、89.9%。结果提示fPSA/tPSA比值对tPSA水平在 2 -2 0 μg/L这组人群前列腺癌诊断的准确率可以大大提高 ,而对此以外的人群并无太大价值。更多还原

【Abstract】 Free-prostate specific antigen (fPSA)/total prostate specific antigen(tPSA) ratio was evaluated in clinical utility. Serum tPSA and fPSA level were measured by eletrochemiluminc scence(ECL) immunoassay and fPSA/tPSA ratio was calculated. Samples were drawn from 38 patients with Pca, 68 patients with BPH and 43 health men. Results showed serum tPSA>4.0μg/L as only cut off for diagnosis Pca, sensitity and specificity of fPSA/tPSA ratio were 84.2%, 75.0% respectivity. But fPSA/tPSA ratio<0.13 for diagnosis Pca; they were 100%, 57.0% respectivity when serum tPSA<2.0μg/L;they were 62.1%, 66.7% when serum tPSA>20.0μg/L; they were 93.6%, 89.9% when serum tPSA was 2-20μg/L. fPSA/tPSA ratio may greatly raised accurate rate for diagnoisis prostate cancer when tPSA level between 2-20μg/L and no value to other patients.更多还原